ISAL 2023 | Using single-cell approaches to study & prevent the progression of clonal hematopoeisis to leukemia
Peter van Galen
• 21 Mar 2023
Peter van Galen, PhD, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Boston, MA, explains how single-cell approaches can help better understand the progression from clonal hematopoiesis (CH) to acute myeloid leukemia (AML), commenting on how this can also help develop strategies to prevent transformation to leukemia and to develop better combination therapies. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
